<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212469</url>
  </required_header>
  <id_info>
    <org_study_id>2016-003293-40</org_study_id>
    <secondary_id>2016/2454</secondary_id>
    <nct_id>NCT03212469</nct_id>
  </id_info>
  <brief_title>A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer</brief_title>
  <acronym>ABIMMUNE</acronym>
  <official_title>A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open label, multicentric, Phase I/II trial aiming to evaluate the safety, the&#xD;
      clinical activity and abscopal anti-tumor effects of a therapeutic strategy associating&#xD;
      Durvalumab in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in&#xD;
      patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is an open label, multicentric, Phase I/II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Event possibly related to study drugs and fulfills any one of the following criteria using CTCAE Version 4.03</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Lung Cancer</condition>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses&#xD;
Safety run of the triple combination:&#xD;
Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,&#xD;
Efficacy step&#xD;
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with&#xD;
SBRT at C1D15, then&#xD;
Durvalumab Q4W alone for up to 9 additional doses</description>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Preliminary steps : Safety Runs&#xD;
Safety run of the triple combination:&#xD;
Tremelimumab at 75mg/Q4W for up to 4 doses&#xD;
Efficacy step&#xD;
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with&#xD;
SBRT at C1D15, then&#xD;
Durvalumab Q4W alone for up to 9 additional doses</description>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>Preliminary steps : Safety Runs&#xD;
Safety run of the dual combination:&#xD;
SBRT at C1D15.&#xD;
Safety run of the triple combination:&#xD;
SBRT at C1D15.&#xD;
Efficacy step&#xD;
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with&#xD;
SBRT at C1D15, then&#xD;
Durvalumab Q4W alone for up to 9 additional doses</description>
    <arm_group_label>Patients lung cancer</arm_group_label>
    <arm_group_label>Patients with head and neck squamous cell carcinoma</arm_group_label>
    <arm_group_label>Patients with oesophagus cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I1. Male or Female patients ≥18 years of age or older. I2. Histologically or cytologically&#xD;
        proven metastatic squamous cell carcinoma (from head and neck, oesophagus, lung, cervix,&#xD;
        vagina, vulva or anus) with the following features:&#xD;
&#xD;
          -  Previously treated with at least one prior regimen (chemotherapy, signal transduction&#xD;
             inhibitors or radiotherapy)&#xD;
&#xD;
          -  To be treated with radiotherapy at primary tumor site or metastatic site or menacing&#xD;
             metastatic site.&#xD;
&#xD;
          -  The sites of metastases allowed are: soft tissue, peripheral lung, and liver.&#xD;
&#xD;
          -  Patients with brain and bone metastasis to be treated with radiotherapy are not&#xD;
             allowed. Patients with asymptomatic brain metastasis can be included.&#xD;
&#xD;
          -  The total tumor volume to be irradiated must not exceed 400 cc. I3. At least one tumor&#xD;
             lesion must be accessible to radiation therapy and at least another tumor site can be&#xD;
             spared from radiation therapy (unirradiated site). I4. At least one unirradiated and&#xD;
             one irradiated tumor site must be accessible to tumor biopsy.&#xD;
&#xD;
        I5. Known availability of an archived block I6. The irradiated and unirradiated tumor sites&#xD;
        must be measurable as per RECIST 1.1 I7. Patients must have no history of previous&#xD;
        radiation therapy within the body area to be irradiated.&#xD;
&#xD;
        I8. Minimal wash-out periods from previous treatments to C1D1 must be&#xD;
&#xD;
          -  Any investigational agent &gt; 4 weeks&#xD;
&#xD;
          -  Bevacizumab &gt; 6 weeks&#xD;
&#xD;
          -  Chemotherapy &gt; 4 weeks&#xD;
&#xD;
          -  TKI &gt; 4 weeks&#xD;
&#xD;
          -  RANK ligand agonists &gt; 6 weeks&#xD;
&#xD;
          -  Immunosuppressive medication &gt; 28 days, with the exceptions of intranasal, topical,&#xD;
             and inhaled corticosteroids or systemic corticosteroids at physiological doses, which&#xD;
             are not to exceeding 10 mg/day of prednisone, or an equivalent corticosteroid&#xD;
&#xD;
          -  Live attenuated vaccination &gt; 30 days I9. WHO 0-1, Performance Status ECOG of 0-1&#xD;
&#xD;
        I10. Patients must have adequate organ function defined as follows:&#xD;
&#xD;
          -  Absolute neutrophil count of ≥ 1500/mm3,&#xD;
&#xD;
          -  Platelet count≥ 100,000/mm3,&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL,&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times the institutional upper limit of normal (ULN). This will not&#xD;
             apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent&#xD;
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or&#xD;
             hepatic pathology), who will be allowed only in consultation with their physician.&#xD;
&#xD;
          -  Serum ALT and AST ≤2.5 ULN (or if liver metastases are present must be ≤ 5x ULN)&#xD;
&#xD;
          -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault&#xD;
             1976) or by 24-hour urine collection for determination of creatinine clearance (see&#xD;
             formula in section 4.1).&#xD;
&#xD;
        I11. Patients must be free of significant comorbid conditions that would preclude safe&#xD;
        administration or completion of protocol therapy.&#xD;
&#xD;
        I12. Female patients must either be of non-reproductive potential (ie, postmenopausal ≥ 12&#xD;
        months with no menses without an alternative medical cause OR history of hysterectomy, OR&#xD;
        history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a&#xD;
        negative serum pregnancy test upon study entry (within 72 hours before study drug start)&#xD;
        I13. Fertile men with a female partner of childbearing potential must agree to use male&#xD;
        condom plus spermicide and childbearing potential women must have agreed to use at least&#xD;
        one highly effective contraceptive method during treatment on this trial and for up to 180&#xD;
        days after the last of dose of Durvalumab + Tremelimumab or 90 days after the last dose of&#xD;
        Durvalumab monotherapy, whichever is the longer period I14. Patient should understand,&#xD;
        sign, and date the written voluntary informed consent form prior to any protocol-specific&#xD;
        procedures performed. Patient should be able and willing to comply with study visits and&#xD;
        procedures as per protocol.&#xD;
&#xD;
        I15. Patients must be affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        E1. Any situation where the irradiation of the target site would imply reirradiation of a&#xD;
        formerly irradiated tumor site.&#xD;
&#xD;
        E2. Patients with any concurrent severe and/or uncontrolled disease which could compromise&#xD;
        participation in the study including:&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3&#xD;
             electrocardiograms (ECGs) using Fredericia's Correction&#xD;
&#xD;
          -  Active or prior documented autoimmune disease within the past 2 years. Of note,&#xD;
             patient with vitiligo, Grave's disease or psoriasis not requiring systemic treatment&#xD;
             (within the past 2 years) are not excluded. Patients with type 1 diabetes or&#xD;
             hypothyroidism stable under treatment or not requiring systemic treatment are&#xD;
             eligible.&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (eg Crohn's disease, ulcerative&#xD;
             colitis)&#xD;
&#xD;
          -  History of primary immunodeficiency&#xD;
&#xD;
          -  Severe chronic or acute infection such as chronic HBV, HCV and HIV1, 2 infection,&#xD;
             active tuberculosis infection&#xD;
&#xD;
          -  Interstitial lung disease that is symptomatic or may interfere with the detection or&#xD;
             management of suspected drug-related pulmonary toxicity or active non-infectious&#xD;
             pneumonitis&#xD;
&#xD;
          -  History of allogenic organ transplant&#xD;
&#xD;
          -  Uncontrolled diabetes,&#xD;
&#xD;
          -  Prior history of active bleeding diathesis or patients taking an oral vitamin K&#xD;
             antagonist (except low-dose Coumadin (warfarin sodium))&#xD;
&#xD;
          -  Symptomatic congestive heart failure,&#xD;
&#xD;
          -  Uncontrolled hypertension,&#xD;
&#xD;
          -  Unstable angina pectoris&#xD;
&#xD;
          -  Cardiac arrhythmia&#xD;
&#xD;
          -  Active peptic ulcer disease or gastritis,&#xD;
&#xD;
          -  Any psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements or compromise the ability of the subject to give written informed consent&#xD;
&#xD;
          -  Active secondary malignancy unless the malignancy is not expected to interfere with&#xD;
             the evaluation of safety and is approved by the sponsor. Examples of the latter&#xD;
             include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix,&#xD;
             and isolated elevation of prostate-specific antigen. Patients with a completely&#xD;
             treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.&#xD;
&#xD;
          -  Chronic treatment with corticosteroids or another immunosuppressant&#xD;
&#xD;
        E3. Patients with tumors that invade major vessels, as shown unequivocally by imaging&#xD;
        studies&#xD;
&#xD;
        E4. Patients with central lung metastasis (i.e within 2 cm from hilum) that are cavitary as&#xD;
        shown unequivocally by imaging studies&#xD;
&#xD;
        E5. Patients with a history of gross hemoptysis (bright red blood of 1/2 teaspoon or more&#xD;
        per episode of coughing) ≤ 3 months prior enrolment&#xD;
&#xD;
        E6. Major surgery within the last 4 weeks prior to entering the study&#xD;
&#xD;
        E7. Persisting significant toxicities related to prior treatments i.e. ≥ Grade 2 AE&#xD;
        according to CTCAE V4.03 except alopecia and biological values defined in inclusion&#xD;
        criteria I10.&#xD;
&#xD;
        E8. Current or planned use of forbidden concomitant medications :&#xD;
&#xD;
          -  Any investigational anticancer therapy not specified in this protocol&#xD;
&#xD;
          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer&#xD;
             treatment. Concurrent use of hormones for noncancer-related conditions (e.g., insulin&#xD;
             for diabetes and hormone replacement therapy) is acceptable.&#xD;
&#xD;
          -  Immunosuppressive medications including, but not limited to systemic corticosteroids&#xD;
             at doses exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine,&#xD;
             and TNF-α blockers. Use of immunosuppressive medications for the management of&#xD;
             investigational product-related AEs or in subjects with contrast allergies is&#xD;
             acceptable. In addition, use of topical, inhaled and intranasal corticosteroids is&#xD;
             permitted.&#xD;
&#xD;
          -  Live attenuated vaccines within 90 days of Durvalumab dosing or within 180 days of&#xD;
             Durvalumab and Tremelimumab dosing. Inactivated vaccines, such as the injectable&#xD;
             influenza vaccine, are authorized.&#xD;
&#xD;
        E9. Any prior Grade ≥ 3 irAE while receiving previous immunotherapy agent or any unresolved&#xD;
        irAE &gt; Grade 1.&#xD;
&#xD;
        E10. Prior exposure to any anti-PD-1 or anti-PD-L1 or anti-CTLA4 antibody E11. Known&#xD;
        allergy or hypersensitivity to humanized antibodies E12. Pregnant or breastfeeding women&#xD;
        E13. Persons deprived of their freedom or under guardianship, or for whom it would be&#xD;
        impossible to undergo the medical follow-up required by the trial, for geographic, social&#xD;
        or psychological reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric DEUTSCH, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric DEUTSCH, MD, PhD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>eric.deutsch@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie LANOY, PhD</last_name>
    <phone>0142114121</phone>
    <phone_ext>+33</phone_ext>
    <email>emilie.lanoy@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric DEUTSCH, MD,PhD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.deutsch@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emilie LANOY, PhD</last_name>
      <phone>0142114121</phone>
      <phone_ext>+33</phone_ext>
      <email>emilie.lanoy@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric DEUTSCH, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

